LifeMax has two wholly owned subsidiaries – LifeMax Laboratories Inc. and LifeMax Biotechnology, Inc.
LifeMax Laboratories Inc. is based in Palo Alto, CA, focused on preclinical, clinical development, regulatory submission and commercialization, whereas LifeMax Biotechnology, Inc. is based in Taipei, Taiwan, focused on exploratory studies and formulation development.
Since inception, LifeMax has raised $40 million in funding with its Series A round closed in 2018.
LifeMax is a clinical stage biotech company with a focus on orphan diseases or diseases that have few or no therapeutics options. Our lead program is ready to enter into Phase IIb/III clinical trial.
LifeMax was founded in late 2014 with $15 million by 4 founders with in-depth full spectrum pharmaceutical industry experience and a successful track record of founding and building a multi-billion dollar publicly traded US company.
Our mission is to engage in research and development, manufacturing, and commercialization of innovative pharmaceutical or biotech products that provide meaningful clinical benefits to patients.
Primarily through licensing and collaboration we have built a strong and balanced portfolio that addresses critical unmet medical needs.
Focused Efforts, Market Driven and Balanced Portfolio are the three pillars of LifeMax’s portfolio strategy.
Focused Efforts
means that we are therapeutically focused on orphan diseases or diseases with few or no therapeutic options. It means that our product development is globally targeted but commercialization is US focused.
Market Driven
means that our portfolio selection is driven by market unmet needs instead of platform technologies. We are focused on delivering clinically meaningful benefits to patients.
Balanced Portfolio
means that we strive to manage the overall risk of the portfolio by a mixture of new chemical/new molecular entities and re-purposed/re-positioned molecules.
Company Overview
Clear and Focused Strategy
